With respect to early diagnosis of internal cancers in patients with CDKN2A variants, there are some encouraging investigational screening protocols for the early detection of pancreatic cancer in high-risk groups (25); however, there is no conclusive evidence to suggest that current methods of pancreatic screening offer any survival benefit (26). Here, CDKN2A is linked to familial pancreatic carcinoma.